Using oral bisphosphonates for the treatment of osteoporosis for at least 5 years approximately doubles the incdience of esophageal cancer per 1,000 population, according to a recent analysis.
Using oral bisphosphonates for the treatment of osteoporosis for at least 5 years approximately doubles the incidence of esophageal cancer per 1,000 population, according to a recent nested case-control analysis from researchers in the United Kingdom.
Using a primary-care cohort of about 6 million people with prospectively recorded information on bisphosphonate prescriptions, researchers found that patients who have taken 1 or more prescriptions for oral bisphosphonates are at about 30% greater risk for developing esophageal cancer than those who have never taken the drugs (relative risk [RR], 1.30; 95% confidence interval [CI], 1.02-1.66; P=.02). Those who have taken 10 or more prescriptions (RR, 1.93; 95% CI, 1.37-2.70) have about twice the risk of those who have taken 1 to 9 prescriptions (RR, 0.93; 95% CI, 0.66-1.31; P for heterogeneity=.002).
Similarly, use of oral bisphosphonates for longer than 3 years (on average, about 5 years) compared with no use was associated with an RR of 2.24 (95% CI, 1.47-3.43). Risk for esophageal cancer did not differ significantly by bisphosphonate type, and risk in those with 10 or more bisphosphonate prescriptions did not vary by age, sex, smoking, alcohol intake, or body mass index; by diagnosis of osteoporosis, fracture, or upper gastrointestinal disease; or by prescription of acid suppressants, nonsteroidal anti-inflammatory drugs, or corticosteroids.
Green J, Czanner G, Reeves G, Watson J, Wise L, Beral V. Oral bisphosphonates and risk of cancer of oesophagus, stomach, and colorectum: case-control analysis within a UK primary care cohort. BMJ. 2010;341:c4444.
Long-term mortality risks for women with adverse pregnancy outcomes
April 19th 2024A recent study revealed that women who experience major adverse pregnancy outcomes face heightened long-term mortality risks, shedding light on the need for comprehensive understanding and preventative measures in women's health.
Read More
Unlocking placenta accreta spectrum with single-cell gene targets
April 18th 2024Discover how cutting-edge single-cell RNA sequencing unveils molecular insights into placenta accreta spectrum disorders, potentially revolutionizing diagnostics and treatments for this life-threatening pregnancy complication.
Read More
Genetics associated with reproductive traits and uterine leiomyomata
April 17th 2024Investigating genetic correlations and shared loci sheds light on potential causal relationships between reproductive traits and uterine leiomyomata, offering insights into their complex interplay and urging further mechanistic exploration.
Read More